Emergent BioSolutions is set to add the only FDA-approved smallpox vaccine to its portfolio through a $125 million deal with vaccine giant Sanofi Pasteur.
The agreement means Emergent will inherit an existing CDC contract to build the national stockpile. That 10-year, $425 million contract has around $160 million left to be fulfilled before it ends in 2018. Emergent expects to negotiate a multiyear renewal as part of its involvement in the U.S. government’s counter-bioterrorism effort.